Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
6 competitors in Chronic Kidney Disease
No patent data available. Pre-approval drugs may not have Orange Book listings.
Tasermity
Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
View on EMAType 2 Diabetes
Squamous Cell Lung Cancer
Type 2 Diabetes
Prostate Cancer
Multiple Myeloma
